107 episodi

A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from Oregon Health & Science University.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.

Plenary Session Vinay Prasad, MD MPH

    • Scienze

A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from Oregon Health & Science University.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.

    2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali

    2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali

    We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries.

    KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7
    Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x

    Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

    Back us on Patreon! www.patreon.com/plenarysession

    • 51 min
    2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat

    2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat

    We have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our first-ever Classical Hematology Chat, featuring our host Dr. Vinay Prasad, Dr. Sven Olson, and Dr. Joseph Shatzel. The chat is on sickle cell disease.

    "A Perspective on the K-Index": doi.org/10.1016/j.jaccas.2020.01.003

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 9 min
    2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein

    2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein

    This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis".

    NELSON: doi.org/10.1056/NEJMoa1911793
    Measures of Uncertainty: doi.org/10.1001/jamanetworkopen.2019.17530

    Back us on Patreon! www.patreon.com/plenarysession

    • 59 min
    2.35 BONUS! How to Keep Up with the New Information in Medicine

    2.35 BONUS! How to Keep Up with the New Information in Medicine

    This BONUS episode is the recording of a lecture given to medical students titled "How to Keep Up with the New Information in Medicine." It's a primer on the steps healthcare professionals need to take in order to keep abreast of the latest medical findings.

    Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h
    2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki

    2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki

    We have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology question of the week from Dr. Emerson Chen of OHSU; and we sit down with Dr. Ali Khaki of the Fred Hutchinson Cancer Research Center to discuss his recent paper critiquing TAILORx.

    Pola for DLBCL: doi.org/10.1200/JCO.19.00172
    Financial COI on Twitter: doi.org/10.1001/jamainternmed.2016.8467
    Ignoring Valuable Data: doi.org/10.6004/jnccn.2019.7363

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 32 min
    2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch

    2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch

    This week we're treating you to a recording of the Grand Rounds lecture on overdiagnosis and cancer screening that Dr. H Gilbert Welch gave at Oregon Health & Science University on October 30, 2019. Before the lecture, we take a moment to reiterate with renewed vigor our distaste for the POLO trial (first discussed in episode 1.64).

    POLO: doi.org/10.1056/NEJMoa1903387

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 13 min

Top podcast nella categoria Scienze

Gli ascoltatori si sono iscritti anche a